

Restoring Liver Health

Promethera Biosciences' mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.

HepaStem for liver rescue therapy

The company's lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in a Phase IIa clinical trial to treat patients with Acute-on-Chronic Liver Failure (ACLF), the program has the potential to target other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatitis (NASH).

Promethera has developed its cell therapy technologies by using allogenic stem and progenitor liver cells. These are isolated, purified and expanded from healthy human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.

TNF-R1 Inhibition - a complementary therapeutic strategy

Promethera has strengthened its development portfolio in 2018 through the acquisition of the Swiss biopharmaceutical company Baliopharm AG. As part of the transaction, Promethera added a complimentary therapeutic strategy to its portfolio of severe liver disease medicines by selectively targeting the TNF-alpha receptor 1 (TNF-R1) and is currently preclinically developing the novel antibody-based monovalent drug candidate Atrosimab towards clinical trials in NASH/Fibrosis indication.

Well positioned for cell therapy excellence

The company was founded in 2009 by Etienne Sokal, Promethera Biosciences' CSMO and Professor of medicine at the Université Catholique de Louvain. It is located within the Walloon healthcare cluster, Biowin, in Belgium. The Walloon region is internationally known for excellence in cell therapy research and is actively supporting Promethera.


In 2016, Promethera acquired Cytonet's key assets, including its US facility based in Durham, North Carolina at the heart of the Research Triangle Park (RTP), an important center for medical research and innovation in the USA.

The acquisition brought a state-of-the-art production facility in the US as well as a powerful network for sourcing ethically-donated human livers from US OPO's (Organ Procurement Organizations) to complement the cGMP facilities and tissue procurement centers in Belgium / UE along with additional experienced leadership and talents.

Broad Investor base

Since inception, Promethera has garnered the support of blue chip venture and corporate venture funds (cfr. page 2) including strategic Japanese and Korean investors, further enabling Promethera's vision of treating patients worldwide.

Product Development Pipeline



ACLF = Acute-on-Chronic Liver Failure | IM = ImmunoModulation | NASH = Non-alcoholic Steatohepatitis

HepaStem, H2Stem are partnered with LifeLiver in Korea

At a Glance

FOUNDED

- > February 12, 2009
- > Acquisition of Cytonet GmbH & Co. KG key assets April 15, 2016
- > Acquisition of Baliopharm AG, April 10, 2018
- > Establishment of a Branch Office in Tokyo, May 14, 2018

MANAGEMENT

- > John Tchelingierian, PhD - President & CEO
- > Etienne Sokal, MD, PhD - Chief Scientific & Medical Officer
- > Mutsuki Takano, MBA - Group Chief Financial Officer & Branch General Manager of Promethera Biosciences Japan Branch
- > Henrik L. Luessen, PhD - Chief Business Officer
- > Mark Johnston, MBA - Chief Commercial Officer Promethera Biosciences Group and MD Promethera Biosciences LLC
- > Bertrand Lellouche - CFO EU/US Financial Operations
- > Jef Pinxteren, PhD - Vice President Operations
- > Paul Smith - Vice President Regulatory Affairs
- > Nathalie Belmonte, PhD - Vice President Product Development
- > Nathalie Clerget, PhD - Vice President Clinical Development

BOARD OF DIRECTORS

- > Charles L. Dimmler III, Chairman of the Board
- > John Tchelingierian, PhD (through Silver Ocean Ventures SAS)
- > Etienne Sokal, Prof, Dr, PhD, Founder
- > Alain Parthoens (through AQ Invest BVBA)
- > Christof Hettich, Prof, Dr
- > Tajio Enoki
- > Reiko Namikawa, M.D., PhD
- > Masaki Doi, PhD
- > Tetsuya Kurihara
- > Edward Haack
- > Masaji Matsuoka, Observer
- > Ingo Koesfeld, Observer
- > Charlie Alexander, Observer
- > Shigeru Yasue, Observer
- > Stephen Chan, Observer


IP POSITION

- > 13 patent families and more than 260 patents and patent applications

RECENT NEWS

- > May 09, 2019: Promethera Biosciences announces First-Dosing in Phase IIa Clinical Study evaluating World's First Liver Stem Cell Therapy in Late-Stage NASH patients
- > May 07, 2019: Promethera Biosciences completes €39.7 Million (\$44.4 Million) Serie D Financing
- > April 15, 2019: Promethera Biosciences presents updated Phase 2a results for world's first stem cell clinical trial in ACLF at the International Liver Congress/EASL 2019


Fully-Formed Supply Chain, Production and Product Platform



Financial Information

EUR 110M raised in equity and semi-equity since inception, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.

MAIN INVESTORS AND SHAREHOLDERS



* Essentially HNWI and private investors.

PROMETHERA Biosciences SA/NV (Headoffice)
Watson & Crick Hill | Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
info@promethera.com

PROMETHERA Biosciences Japan Branch (Japan Operations)
Ueno Building 5F | 1-9-10, Nihonbashi Horidomecho,
Chuo-ku, Tokyo, 103-0012 - Japan
infojapan@promethera.com

PROMETHERA Biosciences LLC (US Operations)
801 Capitola Drive | Suite 8,
Durham NC27713 - U.S.A.
usteam@promethera.com

Baliopharm AG - part of the Promethera Group
Stänzlergasse 4
CH-4051 Basel - Switzerland
info@promethera.com

John Tchelingierian, PhD, President & CEO
John.Tchelingierian@promethera.com

Mutsuki Takano, MBA, Group CFO & Branch General Manager of
Promethera Biosciences Japan Branch
Mutsuki.Takano@promethera.com

www.promethera.com